Immuno-Oncology

Latest News

kidney cancer
Atezolizumab Falls Short in Pretreated, Advanced Renal Cell Carcinoma

June 17th 2023

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Blood draws © adobe.stock.com
Repeated Hematologic Evaluations May Not be Necessary for Patients Receiving ICIs

June 7th 2023

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS
Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

June 3rd 2023

FDA
Trifluridine/Tipiracil, Plus Bevacizumab Under Priority Review for Refractory mCRC

April 24th 2023

melanoma
mRNA Vaccine, Plus Pembrolizumab, Minimizes Recurrence Rate in Melanoma

April 22nd 2023

Video Interviews
Podcasts
Latest CME Events & Activities

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

View More

Miami Breast 2024: Affiliated CE Symposia

March 7, 2024 - March 10, 2024

View More

Dialogues with the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: What Do Current Data for IO- and ALK-Targeted Strategies Tell Us?

March 19, 2024

Register Now!

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

The Latest on Acute Lymphocytic Leukemia

View More

A Focus on Acute Myeloid Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma

View More

Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse

View More

Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

On-Demand Video Updates from the Annual Oncology Meeting

View More

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago

View More

Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC

View More

More News

© 2024 MJH Life Sciences

All rights reserved.